Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Wedbush Sees ~460% Upside in Regulus Therapeutics (RGLS) After Bumping Target to $42
August 5, 2015 1:03 PM EDTWedbush analyst Liana Moussatos reiterated an Outperform rating and boosted her price target on Regulus Therapeutics (NASDAQ: RGLS) to $42.00 (from $41.00) following Q2 results. The analyst projects $139MM cash lasts through 2016 and covers material catalysts.
Moussatos said "With RGLS trading at only... More
Regulus Therapeutics (RGLS) Q2 Revenue Tops Views
August 4, 2015 5:32 PM EDTRegulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.41), may not compare to the analyst estimate of ($0.29). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $2.4 million.
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
... More